{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T12:21:33Z","timestamp":1766060493186,"version":"3.48.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:italic>PIK3CA<\/jats:italic>\n                    is the third most common mutated gene in epithelial cancers, behind only\n                    <jats:italic>TP53<\/jats:italic>\n                    and\n                    <jats:italic>KRAS<\/jats:italic>\n                    . Somatic\n                    <jats:italic>PIK3CA<\/jats:italic>\n                    mutations occur predominantly in the protein\u2019s hotspot locations H1047, E545, E542 and N345, and evidence of those alterations eliciting immune responses has been limited. HLA class I-restricted TCRs against E545K and H1047L have, only recently, been identified following in vitro sensitization (IVS) with peripheral blood lymphocytes (PBL) from normal donors. In this study, we examined the immunogenicity of PIK3CA in patients with epithelial cancers of diverse histology, by testing TIL and antigen-experienced PBL against autologous hotspot PIK3CA mutations. Two distinct TCRs specific to PIK3CA\n                    <jats:sup>N345K<\/jats:sup>\n                    , restricted by HLA-class II pair DPB1*04:01\/DPA1*01:03, were identified in a patient with colon cancer, following independently a TIL screen and an IVS of memory CD4\u2009+\u2009\n                    <jats:italic>T<\/jats:italic>\n                    cells from the peripheral blood. Patient PBL engineered to express each TCR suppressed the in vitro growth of two cell lines modified to express the DPB1*04:01\/DPA1*01:03 pair and full length PIK3CA\n                    <jats:sup>N345K<\/jats:sup>\n                    protein. A TCR specific to the PIK3CA\n                    <jats:sup>E545K<\/jats:sup>\n                    , restricted by HLA-DRB1*04:01, was also identified following IVS of memory CD4\u2009+\u2009PBL from another patient, with rectal cancer. Autologous PBL, gene engineered to express the PIK3CA\n                    <jats:sup>E545K<\/jats:sup>\n                    -specific TCR, suppressed the in vitro growth of two cancer cell lines, which endogenously expressed the PIK3CA\n                    <jats:sup>E545K<\/jats:sup>\n                    neoantigen. This study identified three PIK3CA-specific TCRs against two shared mutations, restricted by common HLA-class II molecules, using antigen-experienced TIL and memory PBL from patients with epithelial cancers and may further allow the development of off-the-shelf\n                    <jats:italic>T<\/jats:italic>\n                    cell immunotherapy strategies targeting PIK3CA.\n                  <\/jats:p>","DOI":"10.1007\/s00262-025-04156-3","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T12:18:16Z","timestamp":1766060296000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Identification of HLA class II-restricted T cell receptors against shared PIK3CA mutations in patients with epithelial cancers"],"prefix":"10.1007","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0037-2766","authenticated-orcid":false,"given":"S. M. Rafiqul","family":"Islam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3193-8718","authenticated-orcid":false,"given":"Samantha","family":"Seitter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7231-5069","authenticated-orcid":false,"given":"Maria","family":"Parkhurst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4620-5293","authenticated-orcid":false,"given":"Frank J.","family":"Lowery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5545-5999","authenticated-orcid":false,"given":"Miaki","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9519-1994","authenticated-orcid":false,"given":"Sanghyun P.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0664-2808","authenticated-orcid":false,"given":"Noam","family":"Levin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2924-3519","authenticated-orcid":false,"given":"Jared J.","family":"Gartner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3260-5982","authenticated-orcid":false,"given":"Satyajit","family":"Ray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5466-4150","authenticated-orcid":false,"given":"Todd","family":"Prickett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2214-2459","authenticated-orcid":false,"given":"Victoria","family":"Hill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1260-8123","authenticated-orcid":false,"given":"Paul F.","family":"Robbins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3317-9804","authenticated-orcid":false,"given":"Stephanie L.","family":"Goff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8939-8910","authenticated-orcid":false,"given":"Steven A.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7103-5591","authenticated-orcid":false,"given":"Nikolaos","family":"Zacharakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"4156_CR1","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1200\/JCO.21.02170","volume":"40","author":"N Zacharakis","year":"2022","unstructured":"Zacharakis N, Huq LM, Seitter SJ et al (2022) Breast cancers are immunogenic: immunologic analyses and a phase II pilot clinical trial using mutation-reactive autologous lymphocytes. J Clin Oncol 40:1741\u20131754. https:\/\/doi.org\/10.1200\/JCO.21.02170","journal-title":"J Clin Oncol"},{"key":"4156_CR2","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1056\/NEJMoa2119662","volume":"386","author":"R Leidner","year":"2022","unstructured":"Leidner R, Sanjuan Silva N, Huang H et al (2022) Neoantigen T-cell receptor gene therapy in pancreatic cancer. N Engl J Med 386:2112\u20132119. https:\/\/doi.org\/10.1056\/NEJMoa2119662","journal-title":"N Engl J Med"},{"key":"4156_CR3","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1126\/science.1251102","volume":"344","author":"E Tran","year":"2014","unstructured":"Tran E, Turcotte S, Gros A et al (2014) Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344:641\u2013645. https:\/\/doi.org\/10.1126\/science.1251102","journal-title":"Science"},{"key":"4156_CR4","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","volume":"375","author":"E Tran","year":"2016","unstructured":"Tran E, Robbins PF, Lu YC et al (2016) T-cell transfer therapy targeting mutant KRAS in cancer. N Engl J Med 375:2255\u20132262. https:\/\/doi.org\/10.1056\/NEJMoa1609279","journal-title":"N Engl J Med"},{"key":"4156_CR5","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1126\/science.aak9510","volume":"356","author":"S Stevanovic","year":"2017","unstructured":"Stevanovic S, Pasetto A, Helman SR et al (2017) Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer. Science 356:200\u2013205. https:\/\/doi.org\/10.1126\/science.aak9510","journal-title":"Science"},{"key":"4156_CR6","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1200\/JCO.2017.74.5463","volume":"35","author":"YC Lu","year":"2017","unstructured":"Lu YC, Parker LL, Lu T et al (2017) Treatment of patients with metastatic cancer using a major histocompatibility complex class II-restricted T-cell receptor targeting the cancer germline antigen MAGE-A3. J Clin Oncol 35:3322\u20133329. https:\/\/doi.org\/10.1200\/JCO.2017.74.5463","journal-title":"J Clin Oncol"},{"key":"4156_CR7","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1158\/2326-6066.CIR-22-0040","volume":"10","author":"SP Kim","year":"2022","unstructured":"Kim SP, Vale NR, Zacharakis N et al (2022) Adoptive cellular therapy with autologous tumor-infiltrating lymphocytes and T-cell receptor-engineered T cells targeting common p53 neoantigens in human solid tumors. Cancer Immunol Res 10:932\u2013946. https:\/\/doi.org\/10.1158\/2326-6066.CIR-22-0040","journal-title":"Cancer Immunol Res"},{"key":"4156_CR8","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1038\/nm0817-1004c","volume":"23","author":"A Zehir","year":"2017","unstructured":"Zehir A, Benayed R, Shah RH et al (2017) Erratum: mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med 23:1004. https:\/\/doi.org\/10.1038\/nm0817-1004c","journal-title":"Nat Med"},{"key":"4156_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0231999","volume":"15","author":"J Rinaldi","year":"2020","unstructured":"Rinaldi J, Sokol ES, Hartmaier RJ, Trabucco SE, Frampton GM, Goldberg ME, Albacker LA, Daemen A, Manning G (2020) The genomic landscape of metastatic breast cancer: insights from 11,000 tumors. PLoS ONE 15:e0231999. https:\/\/doi.org\/10.1371\/journal.pone.0231999","journal-title":"PLoS ONE"},{"key":"4156_CR10","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1038\/s41591-024-03109-0","volume":"30","author":"M Parkhurst","year":"2024","unstructured":"Parkhurst M, Goff SL, Lowery FJ et al (2024) Adoptive transfer of personalized neoantigen-reactive TCR-transduced T cells in metastatic colorectal cancer: phase 2 trial interim results. Nat Med 30:2586\u20132595. https:\/\/doi.org\/10.1038\/s41591-024-03109-0","journal-title":"Nat Med"},{"key":"4156_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-023-01945-y","author":"HR Gurung","year":"2023","unstructured":"Gurung HR, Heidersbach AJ, Darwish M et al (2023) Systematic discovery of neoepitope-HLA pairs for neoantigens shared among patients and tumor types. Nat Biotechnol. https:\/\/doi.org\/10.1038\/s41587-023-01945-y","journal-title":"Nat Biotechnol"},{"key":"4156_CR12","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1038\/s41591-022-01786-3","volume":"28","author":"SS Chandran","year":"2022","unstructured":"Chandran SS, Ma J, Klatt MG et al (2022) Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA. Nat Med 28:946\u2013957. https:\/\/doi.org\/10.1038\/s41591-022-01786-3","journal-title":"Nat Med"},{"key":"4156_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007097","author":"CM Ade","year":"2023","unstructured":"Ade CM, Sporn MJ, Das S et al (2023) Identification of neoepitope reactive T-cell receptors guided by HLA-A*03:01 and HLA-A*11:01 immunopeptidomics. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2023-007097","journal-title":"J Immunother Cancer"},{"key":"4156_CR14","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s00262-024-03729-y","volume":"73","author":"M Shen","year":"2024","unstructured":"Shen M, Chen S, Han X et al (2024) Identification of an HLA-A*11:01-restricted neoepitope of mutant PIK3CA and its specific T cell receptors for cancer immunotherapy targeting hotspot driver mutations. Cancer Immunol Immunother 73:150. https:\/\/doi.org\/10.1007\/s00262-024-03729-y","journal-title":"Cancer Immunol Immunother"},{"key":"4156_CR15","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1158\/2159-8290.CD-18-1494","volume":"9","author":"MR Parkhurst","year":"2019","unstructured":"Parkhurst MR, Robbins PF, Tran E et al (2019) Unique neoantigens arise from somatic mutations in patients with gastrointestinal cancers. Cancer Discov 9:1022\u20131035. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-1494","journal-title":"Cancer Discov"},{"key":"4156_CR16","doi-asserted-by":"publisher","first-page":"5084","DOI":"10.1158\/1078-0432.CCR-21-0849","volume":"27","author":"N Levin","year":"2021","unstructured":"Levin N, Paria BC, Vale NR et al (2021) Identification and validation of T-cell receptors targeting RAS hotspot mutations in human cancers for use in cell-based immunotherapy. Clin Cancer Res 27:5084\u20135095. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0849","journal-title":"Clin Cancer Res"},{"key":"4156_CR17","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/s41467-019-08304-z","volume":"10","author":"G Cafri","year":"2019","unstructured":"Cafri G, Yossef R, Pasetto A et al (2019) Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients. Nat Commun 10:449. https:\/\/doi.org\/10.1038\/s41467-019-08304-z","journal-title":"Nat Commun"},{"key":"4156_CR18","doi-asserted-by":"publisher","first-page":"5289","DOI":"10.1158\/1078-0432.CCR-21-1171","volume":"27","author":"SJ Seitter","year":"2021","unstructured":"Seitter SJ, Sherry RM, Yang JC et al (2021) Impact of prior treatment on the efficacy of adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma. Clin Cancer Res 27:5289\u20135298. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-1171","journal-title":"Clin Cancer Res"},{"key":"4156_CR19","doi-asserted-by":"publisher","first-page":"D783","DOI":"10.1093\/nar\/gkz1029","volume":"48","author":"FF Gonzalez-Galarza","year":"2020","unstructured":"Gonzalez-Galarza FF, McCabe A, Santos E et al (2020) Allele frequency net database (AFND) 2020 update: gold-standard data classification, open access genotype data and new query tools. Nucleic Acids Res 48:D783\u2013D788. https:\/\/doi.org\/10.1093\/nar\/gkz1029","journal-title":"Nucleic Acids Res"},{"key":"4156_CR20","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/s41586-023-06199-x","volume":"618","author":"B Kruse","year":"2023","unstructured":"Kruse B, Buzzai AC, Shridhar N et al (2023) CD4(+) T cell-induced inflammatory cell death controls immune-evasive tumours. Nature 618:1033\u20131040. https:\/\/doi.org\/10.1038\/s41586-023-06199-x","journal-title":"Nature"},{"issue":"91","key":"4156_CR21","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adi9517","volume":"9","author":"EG Bawden","year":"2024","unstructured":"Bawden EG, Wagner T, Schroder J et al (2024) CD4(+) T cell immunity against cutaneous melanoma encompasses multifaceted MHC II-dependent responses. Sci Immunol 9(91):eadi9517. https:\/\/doi.org\/10.1126\/sciimmunol.adi9517","journal-title":"Sci Immunol"},{"key":"4156_CR22","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41591-018-0040-8","volume":"24","author":"N Zacharakis","year":"2018","unstructured":"Zacharakis N, Chinnasamy H, Black M et al (2018) Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat Med 24:724\u2013730. https:\/\/doi.org\/10.1038\/s41591-018-0040-8","journal-title":"Nat Med"},{"key":"4156_CR23","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1097\/CJI.0b013e31824e801f","volume":"35","author":"J Jin","year":"2012","unstructured":"Jin J, Sabatino M, Somerville R, Wilson JR, Dudley ME, Stroncek DF, Rosenberg SA (2012) Simplified method of the growth of human tumor infiltrating lymphocytes in gas-permeable flasks to numbers needed for patient treatment. J Immunother 35:283\u2013292. https:\/\/doi.org\/10.1097\/CJI.0b013e31824e801f","journal-title":"J Immunother"},{"key":"4156_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-016-0288-x","volume":"8","author":"M Nielsen","year":"2016","unstructured":"Nielsen M, Andreatta M (2016) NetMHCpan-3.0; improved prediction of binding to MHC class i molecules integrating information from multiple receptor and peptide length datasets. Genome Med 8:33. https:\/\/doi.org\/10.1186\/s13073-016-0288-x","journal-title":"Genome Med"},{"key":"4156_CR25","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1158\/2326-6066.cir-16-0001","volume":"4","author":"A Pasetto","year":"2016","unstructured":"Pasetto A, Gros A, Robbins PF et al (2016) Tumor- and neoantigen-reactive T-cell receptors can be identified based on their frequency in fresh tumor. Cancer Immunol Res 4:734\u2013743. https:\/\/doi.org\/10.1158\/2326-6066.cir-16-0001","journal-title":"Cancer Immunol Res"},{"key":"4156_CR26","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1126\/science.aad1253","volume":"350","author":"E Tran","year":"2015","unstructured":"Tran E, Ahmadzadeh M, Lu YC et al (2015) Immunogenicity of somatic mutations in human gastrointestinal cancers. Science 350:1387\u20131390. https:\/\/doi.org\/10.1126\/science.aad1253","journal-title":"Science"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04156-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04156-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04156-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T12:18:17Z","timestamp":1766060297000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04156-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["4156"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04156-3","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"assertion":[{"value":"6 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SMRI, SS, MP, FJL, SAR and NZ have a pending patent application. The rest of the authors report no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"5"}}